Julien Potet
Neglected Tropical Disease advisor @msf_access tweeting about #NTDs, #snakebite, #mAbs, #Ebola, #malaria, #VaccinesWork, #MSF & of course #COVID19
Last synced from Twitter 85d ago
Remdesivir Metabolite GS-441524 Efficiently Inhibits SARS-CoV-2 Infection in Mouse Model
The outbreak of coronavirus disease 2019 (COVID-19) rapidly spreads across worldwide and becomes a global pandemic. Remdesivir is the only COVID-19 treatment approved by U.S. Food and Drug Administration (FDA); however, its effectiveness is still...
Lilly announces agreement with U.S. government to supply 300,000 vials of investigational neutralizing antibody bamlanivimab (LY-CoV555) in an effort to fight COVID-19 | Eli Lilly and Company
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
« La question de l'origine du SARS-CoV-2 se pose sérieusement »
Près d'un an après que l'on a identifié le coronavirus SARS-CoV-2, les chercheurs n'ont toujours pas déterminé comment il a pu se transmettre à l'espèce humaine. Le virologue Étienne Decroly fait le point sur les différentes hypothèses, dont celle...
Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq
Objectives: COVID-19 patients suffer from the lack of curative therapy. Hence, there is an urgent need to try repurposed old drugs on COVID-19. Methods: Randomized controlled study on 70 COVID-19 patients (48 mild-moderate, 11 severe, and 11...
Association between Hydroxyzine Use and Reduced Mortality in Patients Hospitalized for Coronavirus Disease 2019: Results from a multicenter observational study
Objective: To examine the association between hydroxyzine use and mortality in patients hospitalized for COVID-19, based on its anti-inflammatory and antiviral properties. Design: Multicenter observational retrospective cohort study. Setting:...
The race to make COVID antibody therapies cheaper and more potent
Injections of antibodies might prevent mild COVID-19 from becoming severe, but the treatments are expensive and difficult to make.
Julien Potet
“What you really want is something that is so amazingly potent that you need barely any" #mAbs #COVID19
87d
ACTIV-3 Statement 2 Title
Eli Lilly and Company
Julien Potet
Rough times for the strategy of "passive immunization" against #COVID19.
Negative results in hospitalized patients for both convalescent plasma (PLACID RCT, India) & @LillyPad's LY-CoV555 (aka bamlanivimab) (ACTIV-3 RCT, US)
lilly.com/news/stories/s…
bmj.com/content/371/bm…
87d
Interventions for the management of snakebite envenoming: An overview of systematic reviews
Author summary Snakebite is a neglected tropical disease which has received priority attention in the global health space with WHO setting a target to decrease death and disability due to snakebite to 50% by 2030. High quality systematic reviews can...
Vitamin D Treatment Is Associated with Reduced Risk of Mortality in Patients with COVID-19: A Cross-Sectional Multi-Centre Observational Study by Stephanie Fenxi Ling, Eleanor Broad, Rebecca Murphy, Joseph Mundattuchundayil Pappachan, Satveer Pardesi-Newt
Background: The 2019 novel coronavirus disease (Covid-19) worldwide pandemic has posed the most substantial and severe public health issue for several generatio
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial
The antiparasitic drug nitazoxanide is widely available and exerts broad-spectrum antiviral activity in vitro. However, there is no evidence of its impact on SARS-CoV-2 infection. In a multicenter, randomized, double-blind, placebo-controlled trial,...
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Objective To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India.
Design Open label, parallel arm, phase II, multicentre, randomised controlled trial.
Setting 39...
Julien Potet
Rough times for the strategy of "passive immunization" against #COVID19.
Negative results in hospitalized patients for both convalescent plasma (PLACID RCT, India) & @LillyPad's LY-CoV555 (aka bamlanivimab) (ACTIV-3 RCT, US)
lilly.com/news/stories/s…
bmj.com/content/371/bm…
87d
Serum Institute Of India
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Partners aim to provide potent neutralizing...
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies
COVID-19 has become a global epidemic, and effective therapies have not been discovered up to now. We conducted this study to explore the effectiveness and safety of tocilizumab recently used for treating COVID-19. A comprehensive search was...
Effect of Tocilizumab on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia
This randomized clinical trial evaluates the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19.
Inhaled antibody drug for COVID-19 clears coronavirus in animals
An inhaled neutralizing antibody cleared the novel coronavirus from infected hamsters at a far lower dose compared with other experimental monoclonal antibodies. The drug is now being developed by Aridis Pharmaceuticals and could offer a...
Julien Potet
While @Regeneron is pushing its high-dose IV anti-SARS2 mAb cocktail (8g !!), researchers are developing inhaled low-dose anti-SARS2 mAbs (2mg-6mg !!). Potentially much cheaper and more user-friendly!
93d
CLINICAL COURSE AND OUTCOME OF COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME: DATA FROM A NATIONAL REPOSITORY
Background: Mortality attributable to coronavirus disease-19 (COVID-19) 2 infection occurs mainly through the development of viral pneumonia-induced acute respiratory distress syndrome (ARDS). Research Question: The objective of the study is to...
Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19 - PubMed
Nitazoxanide demonstrates a good safety profile at approved doses. However, further evidence is required regarding hepatorenal and cardiovascular effects, as well as teratogenicity. We estimate that it would be possible to manufacture nitazoxanide...
Development and pre-clinical characterization of two therapeutic equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy emerges as a promising treatment for COVID-19. Among animal-derived products, equine formulations are still the cornerstone therapy for treating envenomations due to...
Julien Potet
Pre-print: @UniversidadCR in Costa Rica shares the full recipe for their therapeutic equine antiserum for #SARSCoV2. No patent, no trade secret. Other manufacturers can now produce similar products if they wish.
This is open science in practice !
94d